As of April 26, 2023, the company raised $50,000,000 in its first tranche. The round of funding co-led by new investor Arix Bioscience plc, returning investors EQT Life Sciences, SymBiosis Capital Management LLC. The transaction also included participation from new investor Amplitude Ventures, returning investors Andera Partners, Pivotal BioVenture Partners LLC.